ArticleInternational journal of physiology, pathophysiology and pharmacology2011
An anti-coagulation agent Futhan preferentially targets GABA(A) receptors in lungepithelia: implication in treating asthma.
Article in International journal of physiology, pathophysiology and pharmacology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 5 citations in OpenAlex.
- Advances in pulmonary neuroendocrine cells and their cellular interactions in asthma pathogenesis.Frontiers in pharmacology · 2025Review
- Natural killer cells kill extracellular Pseudomonas aeruginosa using contact-dependent release of granzymes B and H.PLoS pathogens · 2022Article
- Nafamostat reduces systemic inflammation in TLR7-mediated virus-like illness.Journal of neuroinflammation · 2022Article
- An autocrine γ-aminobutyric acid signaling system exists in pancreatic β-cell progenitors of fetal and postnatal mice.International journal of physiology, pathophysiology and pharmacology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
Futhan is a serine protease inhibitor and medicine in the treatment of disseminated intravascular coagulation (DIC) and acute pancreatitis. It is metabolized quickly in vivo. Here we show that Futhan reversibly inhibits NMDA receptors in hippocampal neurons and GABA(A) receptors both in hippocampal neurons and in A549 cells, a human alveolar epithelial cell line. The effect of Futhan on GABA(A) receptors in A549 cells is much more potent than its effect on GABA(A) receptors in hippocampal neurons (IC(50): 0.9 μM V.S. 7.3 μM). Since GABA(A) receptors are also expressed in various non-neuronal tissues, particularly in airway epithelia and GABA promotes mucus production during asthma, our findings indicate that Futhan may be developed as a novel aerosolized therapeutic to treat asthma through blocking GABA(A) receptors in the lung.
Indexed as
Identifiers
22162781PMC3230258W1489472680What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.